Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06073574 · ClinicalTrials.gov registry record

CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study

A clinical trial of Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM), sponsored by Ionis Pharmaceuticals.

Active
Registry status
150
Enrollment target
11
Study locations

NCT06073574 is a study of Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) that is active but no longer recruiting, run by Ionis Pharmaceuticals. The registered enrollment target is 150 participants. The trial reports 11 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06073574, a study of Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM), is active but no longer recruiting, sponsored by Ionis Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
150 participants
Enrollment target
11
Study locations

Study Summary

The main purpose of this study is to measure the amyloid burden, defined as extracellular volume (ECV) assessed by Magnetic Resonance Imaging (MRI) over time in a subset of up to 150 participants enrolled in ION-682884-CS2 (NCT04136171).

Conditions Studied

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Interventions

  • DIAGNOSTIC_TEST Cardiac MRI

Study Locations (11)

Other

  • Azienda Ospedaliero - Universitaria Careggi - Florence
  • Azienda Ospedale Università di Padova - Padua
  • Hospital Universitario Puerta de Hierro - Majadahonda
  • Synexus - Scotland Clinical Research Centre - Bellshill
  • Synexus Midlands Clinical Research Centre - Birmingham
  • Synexus - Wales - Cardiff
  • Royal Free London NHS Foundation Trust - London
  • Richmond Pharmacology - London
  • Synexus - Manchester Clinical Research Centre - Manchester

Massachusetts

  • Brigham and Women's Hospital - Boston

Oregon

  • Oregon Health and Science University - Portland

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2021-03-31
Est. Completion 2026-04

Sponsor

Ionis Pharmaceuticals

76 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06073574

The ClinicalTrials.gov registry entry for NCT06073574 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) appearing as the primary indexed condition, and to 1 intervention - of which Cardiac MRI is the first listed.

NCT06073574 reports 11 study locations spanning 3 distinct geographic areas - top geographies include Other, Massachusetts, Oregon.

Frequently Asked Questions

What is clinical trial NCT06073574 about?

NCT06073574 is a clinical study titled "CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study". The main purpose of this study is to measure the amyloid burden, defined as extracellular volume (ECV) assessed by Magnetic Resonance Imaging (MRI) over time in a subset of up to 150 participants enrolled in ION-682884-CS2 (NCT04136171).

What is the current status of trial NCT06073574?

This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2021-03-31. Estimated completion is 2026-04.

What conditions does trial NCT06073574 study?

This clinical trial studies the following conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM).

What interventions are being tested in trial NCT06073574?

The interventions under investigation include: Cardiac MRI (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06073574?

This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06073574 being conducted?

This trial has 11 study locations across Massachusetts, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.